Myovant On Path To Women’s Health Leadership, CEO Says
CEO Lynn Seely talked during a fireside chat at the BIO CEO & Investor meeting about her company’s strategy to build a new women’s health company and even best big pharma rivals.
You may also be interested in...
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.